8 Gene Editing Applications Moving from Lab to Clinical Use

4. Leber Congenital Amaurosis - Restoring Vision Through Gene Correction

Leber Congenital Amaurosis (LCA), a group of inherited retinal dystrophies that cause severe vision loss or blindness from birth, has become a compelling target for in vivo gene editing applications, representing the frontier of treating genetic blindness directly within the eye. This condition, affecting approximately 1 in 80,000 newborns, is caused by mutations in various genes essential for photoreceptor function, with LCA10 (caused by CEP290 mutations) being particularly amenable to gene editing approaches. Unlike systemic gene editing applications, treating LCA involves direct injection of gene editing components into the eye, taking advantage of the organ's immune-privileged status and accessibility. The EDIT-101 trial by Editas Medicine represents the first in vivo CRISPR trial, using a lipid nanoparticle delivery system to transport gene editing components directly to photoreceptor cells in the retina. The treatment aims to correct the specific mutation in the CEP290 gene that causes LCA10, potentially restoring the production of functional protein necessary for vision. Early clinical results have shown the treatment to be well-tolerated, with some patients experiencing improvements in light sensitivity and visual function. This approach is particularly significant because it demonstrates the feasibility of performing gene editing directly in human tissues rather than in extracted cells, opening possibilities for treating other organs and conditions that cannot be addressed through ex vivo editing approaches. The success of ocular gene editing could pave the way for treating other inherited eye diseases and establish protocols for in vivo editing in other organs.